Liaoning Chengda Biotechnology Co. Ltd. A
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company's rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant h… Read more
Market Cap & Net Worth: Liaoning Chengda Biotechnology Co. Ltd. A (688739)
Liaoning Chengda Biotechnology Co. Ltd. A (SHG:688739) has a market capitalization of $1.46 Billion (CN¥10.69 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #9399 globally and #1941 in its home market, demonstrating a 3.05% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Liaoning Chengda Biotechnology Co. Ltd. A's stock price CN¥25.68 by its total outstanding shares 416450000 (416.45 Million).
Liaoning Chengda Biotechnology Co. Ltd. A Market Cap History: 2021 to 2026
Liaoning Chengda Biotechnology Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows change from $3.99 Billion to $1.46 Billion (-21.44% CAGR).
Liaoning Chengda Biotechnology Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Liaoning Chengda Biotechnology Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.87x
Liaoning Chengda Biotechnology Co. Ltd. A's market cap is 0.87 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
4.27x
Liaoning Chengda Biotechnology Co. Ltd. A's market cap is 4.27 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $3.99 Billion | $2.09 Billion | $892.49 Million | 1.91x | 4.47x |
| 2022 | $1.63 Billion | $1.81 Billion | $714.02 Million | 0.90x | 2.28x |
| 2023 | $1.79 Billion | $1.75 Billion | $465.92 Million | 1.02x | 3.84x |
| 2024 | $1.46 Billion | $1.68 Billion | $342.82 Million | 0.87x | 4.27x |
Competitor Companies of 688739 by Market Capitalization
Companies near Liaoning Chengda Biotechnology Co. Ltd. A in the global market cap rankings as of March 19, 2026.
Key companies related to Liaoning Chengda Biotechnology Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Liaoning Chengda Biotechnology Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Liaoning Chengda Biotechnology Co. Ltd. A's market cap moved from $3.99 Billion to $ 1.46 Billion, with a yearly change of -21.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.46 Billion | -0.31% |
| 2025 | CN¥1.46 Billion | -0.08% |
| 2024 | CN¥1.46 Billion | -18.18% |
| 2023 | CN¥1.79 Billion | +10.05% |
| 2022 | CN¥1.63 Billion | -59.23% |
| 2021 | CN¥3.99 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Liaoning Chengda Biotechnology Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.46 Billion USD |
| MoneyControl | $1.46 Billion USD |
| MarketWatch | $1.46 Billion USD |
| marketcap.company | $1.46 Billion USD |
| Reuters | $1.46 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.